Association of Constipation with risk of end-stage renal disease in patients with chronic kidney disease.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
05 08 2019
Historique:
received: 03 01 2019
accepted: 22 07 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 28 10 2020
Statut: epublish

Résumé

Chronic Kidney Disease (CKD) is a growing public health problem. Many risk factors were identified and interventions were applied accordingly, but the incidence of end-stage renal disease continued increasing. Some other risk factors may be ignored. Gut microbiota has been recognized as an important endogenous organ. The kidney-gut axis would contribute to gut dysbiosis, which might worsen CKD. Constipation, commonly seen in CKD, was one of the clinical presentation of gut dysbiosis. The clinical impact of constipation to CKD remains unknown. Our study aimed at assessing the risk of ESRD between CKD patients with and without constipation in a nationwide database. We identified newly diagnosed cases of CKD without constipation history before in 2000-2011 from the Taiwan National Health Insurance database. Subjects who developed constipation later formed constipation group. The others without constipation matched by propensity score formed non-constipation group. The incidence rates and hazards of ESRD in patients with and without constipation by the end of 2013 were compared by using Cox proportional hazard models with a time-dependent variable. The incidences of ESRD per 1000 person-years were 22.9 for constipation group and 12.2 for non-constipation group, respectively. Cox proportional hazard models with a time-dependent variable revealed an adjusted hazard ratio of 1.90 (95% CI, 1.60-2.27). Compared to the CKD patients without constipation, adjusted hazard ratio for the CKD patients with laxatives < 33, 33-197 and ≥ 198 days per year were 0.45 (0.31-0.63), 1.85 (1.47-2.31) and 4.41 (3.61-5.39) respectively. In a population of newly-diagnosed CKD patients, we observed that subjects with de novo constipation, as compared with non-constipation, have increased risk of developing ESRD. More severe constipation would increase the risk further.

Sections du résumé

BACKGROUND
Chronic Kidney Disease (CKD) is a growing public health problem. Many risk factors were identified and interventions were applied accordingly, but the incidence of end-stage renal disease continued increasing. Some other risk factors may be ignored. Gut microbiota has been recognized as an important endogenous organ. The kidney-gut axis would contribute to gut dysbiosis, which might worsen CKD. Constipation, commonly seen in CKD, was one of the clinical presentation of gut dysbiosis. The clinical impact of constipation to CKD remains unknown. Our study aimed at assessing the risk of ESRD between CKD patients with and without constipation in a nationwide database.
METHODS
We identified newly diagnosed cases of CKD without constipation history before in 2000-2011 from the Taiwan National Health Insurance database. Subjects who developed constipation later formed constipation group. The others without constipation matched by propensity score formed non-constipation group. The incidence rates and hazards of ESRD in patients with and without constipation by the end of 2013 were compared by using Cox proportional hazard models with a time-dependent variable.
RESULTS
The incidences of ESRD per 1000 person-years were 22.9 for constipation group and 12.2 for non-constipation group, respectively. Cox proportional hazard models with a time-dependent variable revealed an adjusted hazard ratio of 1.90 (95% CI, 1.60-2.27). Compared to the CKD patients without constipation, adjusted hazard ratio for the CKD patients with laxatives < 33, 33-197 and ≥ 198 days per year were 0.45 (0.31-0.63), 1.85 (1.47-2.31) and 4.41 (3.61-5.39) respectively.
CONCLUSION
In a population of newly-diagnosed CKD patients, we observed that subjects with de novo constipation, as compared with non-constipation, have increased risk of developing ESRD. More severe constipation would increase the risk further.

Identifiants

pubmed: 31382927
doi: 10.1186/s12882-019-1481-0
pii: 10.1186/s12882-019-1481-0
pmc: PMC6683335
doi:

Substances chimiques

Laxatives 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

304

Références

Annu Rev Nutr. 2002;22:283-307
pubmed: 12055347
Kidney Int. 2003 May;63(5):1934-43
pubmed: 12675874
Health Aff (Millwood). 2003 May-Jun;22(3):77-88
pubmed: 12757274
Science. 2005 Mar 25;307(5717):1915-20
pubmed: 15790844
ScientificWorldJournal. 2005 Aug 24;5:652-60
pubmed: 16127597
Cell. 2006 Feb 24;124(4):837-48
pubmed: 16497592
Kidney Int. 2007 Aug;72(3):247-59
pubmed: 17568785
Nephrol Dial Transplant. 2010 Jan;25(1):219-24
pubmed: 19692415
Clin J Am Soc Nephrol. 2009 Oct;4(10):1551-8
pubmed: 19696217
Clin J Am Soc Nephrol. 2010 Jul;5(7):1182-9
pubmed: 20430946
Nephrol Dial Transplant. 2011 Mar;26(3):938-47
pubmed: 20884620
Kidney Int. 2012 Feb;81(3):300-6
pubmed: 22012132
Adv Chronic Kidney Dis. 2012 May;19(3):129-41
pubmed: 22578672
Int Immunopharmacol. 2013 Sep;17(1):108-15
pubmed: 23747589
Diabetes. 1990 Sep;39(9):1116-24
pubmed: 2384191
J Am Soc Nephrol. 2014 Apr;25(4):657-70
pubmed: 24231662
Am J Kidney Dis. 2014 Oct;64(4):510-33
pubmed: 25257325
J Am Soc Nephrol. 2015 Jul;26(7):1732-46
pubmed: 25349205
Microb Ecol Health Dis. 2015 Feb 02;26:26191
pubmed: 25651997
Semin Dial. 2015 Sep-Oct;28(5):459-63
pubmed: 25855516
Curr Opin Biotechnol. 2015 Dec;35:94-102
pubmed: 26070111
J Am Soc Nephrol. 2015 Nov;26(11):2621-33
pubmed: 26209712
Clin J Am Soc Nephrol. 2016 Jun 6;11(6):932-4
pubmed: 27197909
BMC Nephrol. 2016 Sep 30;17(1):141
pubmed: 27716149
J Am Soc Nephrol. 2017 Apr;28(4):1248-1258
pubmed: 28122944
Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F487-F502
pubmed: 29693447
Medicine (Baltimore). 1986 Sep;65(5):291-303
pubmed: 3489155
Nephrol Dial Transplant. 1994;9(3):223-5
pubmed: 8052423

Auteurs

Chung-Yen Lu (CY)

Department of Sport and Health Management, Da-Yeh University, Changhua, 515, Taiwan.
Department of Chinese Medicine, China Medical University Hospital, Taipei Branch, Taipei, 114, Taiwan.
Department of Chinese Medicine, Show Chwan Memorial Hospital, Changhua, 500, Taiwan.

Yin-Cheng Chen (YC)

Department of Internal Medicine, Taipei Hospital, Ministry of Health and Welfare, New Taipei, 242, Taiwan.
Institute of Health Policy and Management, National Taiwan University, No 17, Xu-Zhou Rd, Rm 639, Taipei, 100, Taiwan.

Yu-Wen Lu (YW)

Department of Chinese Medicine, Show Chwan Memorial Hospital, Changhua, 500, Taiwan.
Department of Chinese Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, 505, Taiwan.

Chih-Hsin Muo (CH)

Management Office for Health Data, China Medical University Hospital, Taichung, 404, Taiwan.

Ray-E Chang (RE)

Institute of Health Policy and Management, National Taiwan University, No 17, Xu-Zhou Rd, Rm 639, Taipei, 100, Taiwan. rchang@ntu.edu.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH